Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.

2022 Startups to Watch
stats here
Related Posts on Startland News
Four-day For the Culture Fest arrives in Topeka to celebrate African-American history in Kansas
Startland News’ Startup Road Trip series explores innovative and uncommon ideas finding success in rural America and Midwestern startup hubs outside the Kansas City metro. TOPEKA — Kansas’ capital city has a rich African-American history, Alonzo Harrison said, and it’s time for the community to come together to celebrate the past, present and future. “The Black…
EquipmentShare named to Y Combinator top companies list as it expands across Heartland, opens Ohio center
COLUMBIA, Missouri — Burgeoning construction tech giant EquipmentShare continues to announce plans for growth and expansion in the wake of its $290 million Series E funding round this spring. RELATED: EquipmentShare digs massive $290M round, deepening US footprint, its T3 tech platform Founded in 2015 by brothers Jabbok and Willy Schlacks, EquipmentShare connects contractors with…
Empowered belonging: KC Chamber celebrates inclusive workforce efforts with diversity honors
Diversity is a strength; equity is the objective; and inclusion is the path that unites individuals together, said Amy Lee Sewell. The Greater Kansas City Chamber of Commerce awarded Lockton Companies its 2023 Champion of Diversity award at the annual POWER of Diversity Breakfast. The event brings together the region’s diverse business community to celebrate…
Afraid of needles? This Kansas startup just raised $1M to inject its no-show solution into testing
A fresh funding injection for an Overland Park-based medical device company is expected to help the startup’s products clear federal regulatory hurdles, as well as advance and expand its research and development efforts. Love Lifesciences is on a mission to revolutionize the patient injection experience to make medications both easier and safer to use, said…

